A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

← catalyst calendar

NCT07136467 · readout ≤ 377 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

2,795estimated

Sites

116

Countries

Argentina, Canada, Colombia +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-09-02

actual

When the study began enrolling

Primary completion

Aug 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2027

estimated

The whole study's end, after follow-up

First posted

2025-08-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-Segmental Vitiligo (NSV)
Alopecia Areata
Hidradenitis Suppurativa

Primary outcomes

what the primary-completion date above is the date OF

Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only

measured Up to Day 1

Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only

measured Up to Day 1

Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only

measured Up to Day 1

Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only

measured Up to Day 1

Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only

measured Up to Day 1

Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only

measured Up to Day 1

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed